Drug-eluting stents and other anti-restenosis devices;Stents recubiertos y ortos dispositivos antirreestenosis

Revista Espanola de Cardiologia

Volumn 58, Issue 7, 2005, Pages 842-862

  Moreno, Raúl ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Atherectomy; Drug eluting stent; Intracoronary brachytherapy; Paclitaxel; Restenosis; Sirolimus

Indexed keywords

ABT 578; ANGIOPEPTIN; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; BATIMASTAT; CALCIUM ANTAGONIST; CYCLOSPORIN; DACTINOMYCIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; HALOFUGINONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; IODINE 125; LEFLUNOMIDE; MEPREDNISONE; METALLOPROTEINASE INHIBITOR; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PHOSPHORUS 32; RAPAMYCIN; STRONTIUM 90; TACROLIMUS; TEMSIROLIMUS; TRANILAST; UNINDEXED DRUG; VINCRISTINE; XENON 133; ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT; POLYMER;

ANGIOCARDIOGRAPHY; ATHERECTOMY; BALLOON CATHETER; BRACHYTHERAPY; CARDIOLOGY; CLINICAL TRIAL; CORONARY STENT; DRUG ELUTING STENT; DRUG STRUCTURE; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; METAL IMPLANTATION; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; REVIEW; STANDARDIZATION; STRUCTURE ANALYSIS; TREATMENT WITHDRAWAL; CHEMISTRY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; FORECASTING; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-BACTERIAL AGENTS; ATHERECTOMY, CORONARY; BRACHYTHERAPY; CORONARY RESTENOSIS; DELAYED-ACTION PREPARATIONS; FORECASTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; POLYMERS; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS; TIME FACTORS;

EID: 23644461410     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13077236     Document Type: Article

References (111)

1. Roubin GS, Douglas JS Jr, King SB 3rd, Lin SF, Hutchison N, Thomas RG, et al. Influence of balloon size on initial success, acute complications, and restenosis after percutaneous transluminal coronary angioplasty: a prospective randomized study. Circulation. 1988;78:557-65.
2. Kuntz RE, Baim DS. Defining coronary restenosis. Newer clinical and angiographic paradigms. Circulation. 1993;88:1310-23.
3. Rodríguez AE, Santaera O, Larribau M, Fernández M, Sarmiento R, Pérez Balino, et al. Coronary stenting decreases restenosis in lesions with early loss in luminal diameter 24 hours after successful PTCA. Circulation. 1995;91:1397-402.
4. Knight CJ, Curzen NP, Groves PH, Patel DJ, Goodall AH, Wright C, et al. Stent implantation reduces restenosis in patients with suboptimal results following coronary angioplasty. Eur Heart J. 1999;20:1783-90.
5. Serruys PW, De Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331:489-95.
6. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501.
7. Betriu A, Masotti M, Serra A, Alonso J, Fernández-Avilés F, Gimeno F, et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol. 1999;34:1498-506.
8. Moreno R, Fernández C, Alfonso F, Hernández RA, Pérez MJ, Escaned J, et al. Coronary stenting in small vessels. A meta-analysis from eleven randomized trials. J Am Coll Cardiol. 2004;43:1964-72.
9. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676-88.
10. Gregorini L, Marco J, Fajadet J, Bernies M, Cassagneau B, Brunel P, et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol. 1997;29:13-20.
11. Bauters C, Hubert E, Prat A, Bougrimi K, Van Belle E, McFadden EP, et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol. 1998;31:1291-8.
12. Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, et al. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol. 1995;26:720-4.
13. Castagna MT, Mintz GS, Leiboff BO, Ahmed JM, Mehran R, Satler LF, et al. The contribution of «mechanical» problems to in-stent restenosis: An intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. Am Heart J. 2001; 142:970-4.
14. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J. 1999;20:58-69.
15. Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2002; 106:1243-50.
16. Gregory CR, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation. 1993;55: 1409-18.
17. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Markx AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277-83.
18. Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel DI, Schroder S, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol. 2000;35:1969-76.
19. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-80.
20. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23.
21. Schofer J, Schluter M, Gershlick AH, Wijns W, García E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093-9.
22. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110-5.
23. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004;292:2727-34.
24. Alfonso F, Ángel J, Cequier A, Augé JM, López Mínguez JR, Bethencourt A, et al. Results of the restenosis intrastent: balloon angioplasty versus rapamycin-eluting stent implantation randomized study. J Am Coll Cardiol. 2005;45:A83.
25. Kastrati A, Mehilli J, Von Beckerath N, Dibra A, Hausleiter J, Pache J, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293:165-71.
26. Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Gómez-Hospital JA, Hernández-Antolín R, Goicolea J, et al. The diabetes and sirolimus-eluting stent diabetes trial: one-year clinical results. J Am Coll Cardiol. 2005;45:A70.
27. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289-95.
28. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-45.
29. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation. 2004;109:1948-54.
30. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation. 2004;109:487-93.
31. Grube E, Lansky A, Hauptmann KE, Di Mario C, Di Sciascio G, Colombo A, et al. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol. 2004;44:1368-72.
32. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
33. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-94.
34. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350: 221-31.
35. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR. Jr, Spanos V, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation. 2004;109:1244-9.
36. Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol. 2004;43: 704-8.
37. Hoye A, Lemos PA, Arampatzis CA, Saia F, Tanabe K, Degertekin M, et al. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol. 2004;16:230-3.
38. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Matteo M, et al. Treatment of saphenous vein grafts lesions with drug-eluting stents: immediate and mid-term outcome. J Am Coll Cardiol. 2005;45:A25.
39. De Lezo JS, Medina A, Pan M, Delgado A, Segura J, Pavlovic D, et al. Rapamycin-eluting stents for the treatment of unprotected left main coronary disease. Am Heart J. 2004;148:481-5.
40. Arampatzis CA, Lemos PA, Tanabe K, Hoye A, Degertekin M, Saia F, et al. Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. Am J Cardiol. 2003; 92:327-9.
41. Hoye A, Tanabe K, Lemos PA, Aoki J, Saia F, Arampatzis C, et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol. 2004;43:1954-8.
42. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study: the Rapamune US Study Group. Lancet. 2000;356:194-202.
43. Brattstrom C, Wilczek H, Tyden G, Bottiger Y, Sawe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation. 1998;65:1272-4.
44. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 1993;20:1-15.
45. Babinska A, Markell MS, Salifu MO, Akoad M, Ehrlich YH, Kornecki E. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant. 1998; 13:3153-9.
46. Moreno R, Fernández C, Hernández R, Alfonso F, Angiolillo DJ, Sabate M, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954-9.
47. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation. 2005;111:1040-4.
48. A Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. Prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol. 2005;45:308-11.
49. Morice MC. The REALITY trial. Sesiones científicas del ACC, 2005 [accedido 28 Abr 2005]. Disponible en: http://www.tctmd.com/display/expert/pdf/132178/CRDUS_REALITY.pdf
50. Windecker S. The SIRTAX trial. Sesiones científicas del ACC, 2005 [accedido 28 Abr 2005]. Disponible en: http://www.tctmd.com/display/expert/pdf/129315/Windecker_F1215.pdf
51. Kastrati A. The ISAR-DIABETES trial. Sesiones científicas del ACC, 2005 [accedido 28 Abr 2005]. Disponible en: http://www.tctmd.com/display/expert/pdf/135010/Kastrati_slides.pdf
52. Suárez de Lezo J, Medina A, Pan M, Romero M, Delgado A, Segura J, et al. Drug-eluting stent for complex lesions: latest angiographic data from the randomized rapamycin versus paclitaxel CORPAL study. J Am Coll Cardiol. 2005;45:A75.
53. Oliva G, Espallargues M, Pons JM. Stents recubiertos de fármacos antiproliferativos: revisión sistemática del beneficio y estimación del impacto presupuestario. Rev Esp Cardiol. 2004;57: 617-28.
54. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999; 100:1872-8.
55. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30:1428-36.
56. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103:2816-21.
57. Koster R, Vieluf D, Kiehn M, Sommerauer M, Kahler J, Baldus S, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet. 2000;356:1895-7.
58. Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2003; 107:24-7.
59. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, Van der Giessen WJ, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003;107:559-64.
60. Degertekin M, Regar E, Tanabe K, Smits PC, Van der Giessen WJ, Carlier SG, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol. 2003;41:184-9.
61. Teirstein PS, Kao J, Bass TA, Costa MA, Yakubov S, Carter AJ, et al. Use of the sirolimus eluting BX velocity stent for failed brachytherapy in recurrant in-stent restenosis: the results of the SECURE Registry. J Am Coll Cardiol. 2003;41:A48.
62. Waksman R, Torguson R, Ajan AE, Cheneau E, Chan RC, Bass B, et al. Drug eluting stents versus repeat vascular brachytherapy for patients with recurrent of in-stent restenosis who failed radiation therapy. J Am Coll Cardiol. 2005;45:A44.
63. Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, Van der Giessen WJ, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation. 2004;109:1366-70.
64. Colombo A, Orlic D, Stankovic G, Corvaja N, Spanos V, Montorfano M, et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation. 2003;107:2178-80.
65. Kapoor S. The angiographic pattern of restenosis after paclitaxel-eluting stents. Am J Cardiol. 2003;92:L56.
66. Angiolillo DJ, Sabate M, Jiménez-Quevedo P, Alfonso F, Galván C, Fernández JM, et al. Intracoronary brachytherapy following drug-eluting stent failure. It's still not time to hang up the spikes! Cardiovasc Radiat Med. 2003;4:171-5.
67. Eltchaninoff H, Koning R, Tron C, Gupta V, Cribier A. Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate. J Am Coll Cardiol. 1998;32:980-4.
68. Alfonso F, Pérez-Vizcayno MJ, Hernández R, Goicolea J, Fernández-Ortiz A, Escaned J, et al. Long-term outcome and determinants of event-free survival in patients treated with balloon angioplasty for in-stent restenosis. Am J Cardiol. 1999;83:1268-70.
69. Bossi I, Klersy C, Black AJ, Cortina R, Choussat R, Cassagneau B, et al. In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol. 2000;35:1569-76.
70. Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, López-Minguez JR, et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol. 2003;42:796-805.
71. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med. 1993;329: 221-7.
72. Simonton CA, Leon MB, Baim DS, Hinohara T, Kent KM, Bersin RM, et al. «Optimal» directional coronary atherectomy: final results of the Optimal Atherectomy Restenosis Study (OARS). Circulation. 1998;97:332-9.
73. Dill T, Dietz U, Hamm CW, Kuchler R, Rupprecht FU, Haude M, et al. A randomized comparison of balloon angioplasty versus rotational atherectomy in complex coronary lesions (COBRA study). Eur Heart J. 2000;21:1759-66.
74. Reifart N, Vandormael M, Krajcar M, Gohring S, Preusler W, Schwarz F, et al. Randomized comparison of angioplasty of complex coronary lesions at a single center. Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study. Circulation. 1997;96:91-8.
75. Moreno R, García E, Soriano J, Acosta J, Abeytua M. Long-term outcome of patients with proximal left anterior descending coronary artery in-stent restenosis treated with rotational atherectomy. Catheter Cardiovasc Interv. 2001;52:435-42.
76. Sharma SK, Kini A, Mehran R, Lansky A, Kobayashi Y, Marmur JD. Randomized trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-stent Restenosis (ROSTER). Am Heart J. 2004;147:16-22.
77. Vom Dahl J, Dietz U, Haager PK, Silber S, Niccoli L, Buettner HJ, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). Circulation. 2002;105:583-8.
78. Mauri L, Bonan R, Weiner BH, Legrand V, Bassand JP, Popma JJ, et al. Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. Am J Cardiol. 2002;90:1079-83.
79. Izumi M, Tsuchikane E, Funamoto M, Kobayashi T, Sumitsuji S, Otsuji S, et al. Final results of the CAPAS trial. Am Heart J. 2001;142:782-9.
80. Moris C, Bethencourt A, Gómez-Recio M, Bordes P, Augé J, Melgares R, et al. Angiographic follow-up of cutting balloon vs conventional balloon angioplasty: results of the CUBA study. J Am Coll Cardiol. 1998;31:A223.
81. Ozaki Y, Suzuki T, Yamaguchi T, Nakamura M, Kitayama M, Nishikawa H, et al. Can intravascular ultrasound guided cutting balloon angioplasty before stenting be a substitute for drug-eluting stents? Final results of the prospective randomized multicenter trial comparing cutting balloon with balloon angioplasty before stenting [Reduce-III]. J Am Coll Cardiol. 2004;43:A82.
82. Iijima R, Ikari Y, Anzai H, Nishida T, Tsunoda T, Nakamura M, et al. The impact of cutting balloon angioplasty for the treatment of diffuse in-stent restenosis. J Invasive Cardiol. 2003;15:427-31.
83. Chevalier B, Royer T, Guyon P, Glatt B. Treatment of in-stent restenosis: short and midterm results of a pilot randomized study between balloon and cutting balloon. J Am Coll Cardiol. 1999; 33:A62.
84. Mizobe M, Oohata K, Osada T. The efficacy of cutting balloon for in-stent restenosis compared with conventional balloon angioplasty. Circulation. 1999;100:1308.
85. Albiero R, Silber S, Di Mario C, Cernigliaro C, Battaglia S, Reimers B, et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). J Am Coll Cardiol. 2004;43:943-9.
86. Montorsi P, Galli S, Fabbiocchi F, Trabattoni D, Ravagnani PM, Bartorelli AL. Randomized trial of conventional balloon angioplasty versus cutting balloon for in-stent restenosis. Acute and 24-hour angiographic and intravascular ultrasound changes and long-term follow-up. Ital Heart J. 2004;5:271-9.
87. Stone GW, De Marchena E, Dageforde D, Foschi A, Muhlestein JB, McIvor M, et al. Prospective, randomized, multicenter comparison of laser-facilitated balloon angioplasty versus stand-alone balloon angioplasty in patients with obstructive coronary artery disease. The Laser Angioplasty Versus Angioplasty (LAVA) Trial Investigators. J Am Coll Cardiol. 1997;30:1714-21.
88. Appelman YE, Piek JJ, Strikwerda S, Tijssen JG, De Feyter PJ, David GK, et al. Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease. Lancet. 1996;347:79-84.
89. Koster R, Hamm CW, Seabra-Gomes R, Herrmann G, Sievert H, Macaya C, et al. Laser angioplasty of restenosed coronary stents: results of a multicenter surveillance trial. The Laser Angioplasty of Restenosed Stents (LARS) Investigators. J Am Coll Cardiol. 1999;34:25-32.
90. Fitzgerald PJ, Takagi A, Moore MP, Hayase M, Kolodgie FD, Corl D, et al. Intravascular sonotherapy decreases neointimal hyperplasia after stent implantation in swine. Circulation. 2001; 103:1828-31.
91. Serruys PW, Hoye A, Grollier G, Colombo A, Symons J, Mudra H. A european multi-center trial investigating the anti-restenotic effect of intravascular sonotherapy after stenting of de novo lesions (EUROSPAH: EUROpean Sonotherapy Prevention of Arterial Hyperplasia). Int J Cardiovasc Intervent. 2004;6:53-60.
92. Wiedermann JG, Marboe C, Amols H, Schwartz A, Weinberger J. Intracoronary irradiation markedly reduces restenosis after balloon angioplasty in a porcine model. J Am Coll Cardiol. 1994; 23:1491-8.
93. Cottin Y, Kollum M, Chan RC, Kim H, Bhargava B, Vodovotz Y, et al. Differential remodeling after balloon overstretch injury and either beta- or gamma-intracoronary radiation of porcine coronary arteries. Cardiovasc Radiat Med. 2001;2:75-82.
94. Condado JA, Waksman R, Gurdiel O, Espinosa R, Gonzalez J, Burger B, et al. Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. Circulation. 1997;96:727-32.
95. Verin V, Urban P, Popowski Y, Schwager M, Nouet P, Dorsaz PA, et al. Feasibility of intracoronary beta-irradiation to reduce restenosis after balloon angioplasty. A clinical pilot study. Circulation. 1997;95:1138-44.
96. Serruys PW, Wijns W, Sianos G, De Scheerder I, Van den Heuvel PA, Rutsch W, et al. Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term anti-platelet treatment: results of a randomized trial: Beta-Radiation Investigation with Direct Stenting and Galileo in Europe (BRIDGE). J Am Coll Cardiol. 2004;44:528-37.
97. King SB 3rd, Williams DO, Chougule P, Klein JL, Waksman R, Hilstead R, et al. Endovascular beta-radiation to reduce restenosis after coronary balloon angioplasty: results of the beta energy restenosis trial (BERT). Circulation. 1998;97:2025-30.
98. Raizner AE, Oesterle SN, Waksman R, Serruys PW, Colombo A, Lim YL, et al. Inhibition of restenosis with beta-emitting radiotherapy: report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation. 2000;102:951-8.
99. Verin V, Popowski Y, De Bruyne B, Baumgart D, Sauerwein W, Lins M, et al. Endoluminal beta radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding study group. N Engl J Med. 2001;344:243-9.
100. Sabate M, Pimentel G, Prieto C, Corral JM, Banuelos C, Angiolillo DJ, et al. Intracoronary brachytherapy after stenting de novo lesions in diabetic patients: results of a randomized intravascular ultrasound study. J Am Coll Cardiol. 2004;44:520-7.
101. Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001;344:250-6.
102. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 1997;336:1697-703.
103. Waksman R, White RL, Chan RC, Bass BG, Geirlach L, Mintz GS, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation. 2000;101:2165-71.
104. Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet. 2002;359:551-7.
105. Waksman R, Cheneau E, Ajani AE, White RL, Pinnow E, Torguson R, et al. Intracoronary radiation therapy improves the clinical and angiographic outcomes of diffuse in-stent restenotic lesions: results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies. Circulation. 2003;107:1744-9.
106. Grise MA, Massullo V, Jani S, Popma JJ, Russo RJ, Schatz RA, et al. Five-year clinical follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation. 2002;105:2737-40.
107. Waksman R, Bhargava B, White L, Chan RC, Mehran R, Lansky AJ, et al. Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation. 2000;101:1895-8.
108. 90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation. 2002;106:1090-6.
109. Okura H, Lee DP, Lo S, Yeung AC, Honda Y, Waksman R, et al. Late incomplete apposition with excessive remodeling of the stented coronary artery following intravascular brachytherapy. Am J Cardiol. 2003;92:587-90.
110. Sabate M, Costa MA, Kozuma K, Kay IP, Van der Giessen WJ, Coen VL, et al. Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy. Circulation. 2000;101:2467-71.
111. Albiero R, Nishida T, Adamian M, Amato A, Vaghetti M, Corvaja N, et al. Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. Circulation. 2000;101:2454-7.